KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other financing activities (2020 - 2025)

Royalty Pharma's Other financing activities history spans 5 years, with the latest figure at -$15.3 million for Q4 2025.

  • For Q4 2025, Other financing activities fell 170.85% year-over-year to -$15.3 million; the TTM value through Dec 2025 reached $7.7 million, down 67.82%, while the annual FY2025 figure was -$1.8 million, 114.19% down from the prior year.
  • Other financing activities for Q4 2025 was -$15.3 million at Royalty Pharma, down from $21.6 million in the prior quarter.
  • Across five years, Other financing activities topped out at $21.6 million in Q4 2024 and bottomed at -$15.3 million in Q4 2025.
  • The 4-year median for Other financing activities is $1.1 million (2021), against an average of $3.5 million.
  • The largest annual shift saw Other financing activities skyrocketed 430.46% in 2021 before it crashed 170.85% in 2025.
  • A 4-year view of Other financing activities shows it stood at $801000.0 in 2021, then surged by 68.16% to $1.3 million in 2022, then skyrocketed by 1506.61% to $21.6 million in 2024, then plummeted by 170.85% to -$15.3 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other financing activities are -$15.3 million (Q4 2025), $21.6 million (Q4 2024), and $2000.0 (Q3 2024).